Mad Money with Jim Cramer – Episode Summary (January 16, 2025)

Release Date: January 17, 2025

1. Economic and Political Commentary

Jim Cramer opens the episode by delving into the impact of the Biden administration's policies on the economy and Wall Street. He discusses the sentiment among CEOs who believe that the administration's approach has been antagonistic towards big business, leading to regulatory challenges and stifled growth in various industries.

• Impact on Big Pharma: Cramer highlights the Inflation Reduction Act (IRA) and its provisions allowing Medicare to negotiate drug prices. He notes CEOs' frustrations with “the endless parade of new regulations stifling important industries” (04:45).

• Semiconductor Sector: He contrasts the IRA's challenges with the positive effects of the Chips and Science Act, though he criticizes the unequal distribution of subsidies, particularly favoring Intel (06:30).

• Fossil Fuels vs. Renewables: Cramer discusses how oil companies have managed to prosper despite the administration's skepticism towards fossil fuels, attributing their success to a lack of dialogue with the President (07:15).

• Banking Industry: The bank sector, despite regulatory pressures, has seen significant profitability. Cramer emphasizes the need for a balanced relationship between the government and businesses to foster growth (09:00).

Notable Quote:

"Mad Money starts now. Hey, I'm Cramer. Welcome to Mad Money. My mission is simple: to make you money." (01:21)

2. Interview with Dr. Vlad Schor – CEO of Biohaven

Cramer sits down with Dr. Vlad Schor, Chairman and CEO of Biohaven Ltd., to discuss the company's advancements and future pipeline. Biohaven, known for its successful migraine drug sold to Pfizer, is expanding into treatments for OCD, epilepsy, bipolar disorder, obesity, and oncology.

• Innovative Treatments: Dr. Schor highlights Biohaven's unique approach to treating mania and epilepsy by targeting the KV7 ion channel, aiming to reduce side effects commonly associated with older medications (16:24).

• Precision Immunology: The company is pioneering in precision immunology, inspired by precision oncology, to develop targeted therapies that minimize impact on healthy immune functions (17:01).

• Future Prospects: Dr. Schor emphasizes the potential of their new therapies to provide more effective and less debilitating treatments for various neurological conditions (19:14).

Notable Quote:

"We're looking at some innovative approaches, new mechanisms that no one's ever explored today. And we have to do that for patients because when you look at our older drugs, they're indirectly hitting these diseases and frankly, they're not good enough for patients." – Dr. Vlad Schor (15:51)

3. Interview with Brian Jordan – CEO of First Horizon

Cramer discusses the performance and outlook of regional banks with Brian Jordan, Chairman and CEO of First Horizon. Despite a slight revenue miss, First Horizon has shown resilience with strong credit quality and strategic portfolio management.

• Economic Optimism: Jordan expresses confidence in the Southeast region's economic growth, supported by favorable demographic trends and business-friendly policies (23:28).

• Interest Rates Outlook: He adopts a cautious stance on future rate cuts, anticipating minimal adjustments unless significant economic shifts occur (24:58).

• Regulatory Environment: Jordan advocates for tailored regulations based on the size and systemic importance of financial institutions, suggesting that smaller banks like First Horizon face different challenges compared to giants like JPMorgan (25:35).

Notable Quote:

"Our charge-offs have been very contained. We feel good about our credit performance year over year – we're down about 10 basis points. So that really goes to the quality of our underwriting." – Brian Jordan (23:47)

4. Interview with Todd McKinnon – CEO of Okta

In a conversation about cybersecurity, Todd McKinnon, Co-founder and CEO of Okta, discusses the implications of the Biden administration's executive order on U.S. cybersecurity standards and its effects on the industry.

• Identity Verification Importance: McKinnon underscores the critical role of identity verification in preventing security breaches, noting that 80% of cyberattacks involve compromised identities (32:48).

• Government Partnerships: Okta's strong relationships with federal agencies, including the Department of Defense, position the company well to benefit from increased cybersecurity investments (31:56).

• Future of Identity Security: McKinnon emphasizes the necessity of independent and neutral identity platforms to provide flexibility and robust security, especially as AI technologies evolve (35:43).

Notable Quote:

"We're trying to lead the fight against these identity-based attacks. If we can solve these, we can address 80% of security breaches, which is a huge progress to make." – Todd McKinnon (32:48)

5. Callers' Questions and Responses

The episode features several callers seeking Jim Cramer's advice on various stocks:

• Rizwan from Texas: Seeks advice on Disney (DIS) amidst recent local fires. Cramer advises buying Disney, citing its resilience and strong franchise (09:01).

• Caller on Palantir (PLTR): Requests guidance on holding versus selling shares. Cramer recommends holding and buying back if prices drop, praising Palantir's data analysis capabilities (09:26).

• Trey from Texas: Asks about VF Corp (VFC) amidst personal financial strain. Cramer humorously suggests betting on VF Corp to save his marriage and anticipates the stock will rise (10:46).

• Aaron from Rhode Island: Inquires about Amazon (AMZN) performance. Cramer maintains a long-term bullish stance on Amazon, advocating for continued investment (40:06).

Notable Quote:

"When Jim Cramer talks, I listen." – Caller recalling Jim's influence and success with Palantir (09:28)

6. Lightning Round

In the high-energy Lightning Round segment, Cramer answers rapid-fire questions from callers about various stocks:

• Best Buy (BBY): Despite past challenges, Cramer remains optimistic, urging holds due to its solid fundamentals and future potential (41:18).

• Berkshire Financial (BFS): Cramer endorses Berkshire for its strong execution and market presence, recommending it as a buy (42:09).

• Other Stocks: Cramer offers quick takes on Alignment Health Care and other companies, emphasizing due diligence and strategic holds or buys based on company performance (40:50).

Notable Quote:

"Stocks performed well during the Biden administration's tenure, at least in the aggregate. But was it in spite of his policies?" (01:21)

7. Semiconductor Industry Analysis

Cramer critiques recent U.S. government policies affecting the semiconductor industry, particularly the restrictions imposed on Nvidia's high-end chip sales to certain countries. He expresses frustration over the selective nature of these restrictions, arguing that they undermine the industry's global competitiveness.

• Nvidia Restrictions: Cramer deems the Biden administration's decision to limit high-end chip exports to countries like Israel, Mexico, Portugal, and Switzerland as arbitrary and counterproductive (48:16).

• Taiwan Semiconductor Manufacturing (TSMC): Despite strong orders from TSMC, Cramer observes that the stock remains undervalued, attributing this to regulatory uncertainties (48:16).

• Chinese Accusations: He discusses China's claims that the U.S. Chips and Science Act unfairly supports domestic semiconductor companies, highlighting the ongoing trade tensions (48:16).

Notable Quote:

"The whole new regime seems unnecessarily restrictive to me... Maybe we can salvage it, but maybe we can't." – Jim Cramer (48:16)

8. Closing Remarks

Cramer wraps up the episode by reiterating his bullish outlook on various sectors and stocks discussed throughout the show. He emphasizes the importance of strategic investments and staying informed to navigate the complexities of the current market landscape.

Notable Quote:

"Bull market summer. I promise to find it just for you right here on Mad Money." – Jim Cramer (48:16)

Conclusion

This episode of Mad Money with Jim Cramer offers a comprehensive analysis of the interplay between government policies and business performance, insightful interviews with industry leaders in biotech, banking, and cybersecurity, as well as actionable investment advice through caller interactions and the Lightning Round. Cramer's critiques of policy decisions, especially those affecting the semiconductor industry, provide viewers with a deeper understanding of the factors influencing market movements.

Note: All timestamps correspond to the transcript provided and are intended to reference key moments within the episode.